A-1 Price List - Arbli - Renin-Angiotensin Antihypertensives - Angiotensin II Receptor Blockers.xlsx
XLSX spreadsheet 50 KB Posted
- Solicitation number
- HT9402-25-Q-9304
- Issued by
-
Defense Health Agency
About this file
This Excel file is a Price List for the Department of Defense (DoD) Uniform Formulary Blanket Purchase Agreement (UF BPA) and Additional Discount Program (ADP) for Renin-Angiotensin Antihypertensives - Angiotensin II Receptor Blockers, scheduled for review at the August 6-7, 2025 P&T Committee meeting. The document provides pricing and formulary scenarios for up to 10 newly approved drugs, with quotes due on July 28, 2025, and includes multiple pricing and reimbursement scenarios such as Uniform Formulary, Tier 2, and Tier 3 classifications across different step therapy conditions.
The file outlines complex pricing mechanisms including non-FAMP (Federal Acquisition Medicaid Price) calculations, Wholesale Acquisition Cost (WAC) discounts, and potential prior authorization requirements. Manufacturers are required to submit fully executed signature pages with quote information, and the P&T Committee retains discretion to recommend preferential pricing, cost-sharing adjustments, or potential exclusion from the TRICARE pharmacy benefit program. The document is part of the DoD's statutory requirement to establish an efficient, integrated pharmacy benefits program for the Military Health System, with specific focus on evaluating clinical and cost-effectiveness of pharmaceutical agents.
View the file
Other files
Show all 30
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the August 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 |
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Grandfathering: a prior authorization process would require all new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user.
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 104RAAS2UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 104RAAS2UFST3 | Uniform Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| 104RAAS2NFST3 | Non-Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 104RAAS2UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 104RAAS2UFST3 | Uniform Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| 104RAAS2NFST3 | Non-Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 104RAAS2UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 104RAAS2UFST3 | Uniform Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| 104RAAS2NFST3 | Non-Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 104RAAS2UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 104RAAS2UFST3 | Uniform Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| 104RAAS2NFST3 | Non-Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 104RAAS2UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 104RAAS2UFST3 | Uniform Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| 104RAAS2NFST3 | Non-Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 104RAAS2UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 104RAAS2UFST3 | Uniform Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| 104RAAS2NFST3 | Non-Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 104RAAS2UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 104RAAS2UFST3 | Uniform Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| 104RAAS2NFST3 | Non-Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 104RAAS2UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 104RAAS2UFST3 | Uniform Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| 104RAAS2NFST3 | Non-Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 104RAAS2UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 104RAAS2UFST3 | Uniform Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| 104RAAS2NFST3 | Non-Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 104RAAS2UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 104RAAS2UFST3 | Uniform Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| 104RAAS2NFST3 | Non-Formulary | ||||
| After Step Therapy | 3 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (non-FAMP Discount)
| UF ADP Appendix for the August 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 |
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Grandfathering: a prior authorization process would require all new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user.
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (WAC Discount)
| UF ADP Appendix for the August 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 |
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Grandfathering: a prior authorization process would require all new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user.
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | RENIN-ANGIOTENSIN ANTIHYPERTENSIVES | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ANGIOTENSIN II RECEPTOR BLOCKERS | Quotes due: | July 28, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 104RAAS2T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 104RAAS2T2AS3 | Tier 2 | ||||
| After Step Therapy | 3 or more | ||||
| 104RAAS2T3AS3 | Tier 3 | ||||
| After Step Therapy | 3 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
File details come from the government source that posted it. Updated .